Iluvien

Fluocinolone acetonide, the active ingredient in Iluvien, is a glucocorticoid presented as a 0.19 mg intravitreal implant for intravitreal injection use. It is indicated for the treatment of diabetic macular edema in adult patients, helping to reduce retinal swelling and improve visual acuity.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, ophthalmology clinics and specialty eye centres worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable logistics and post‑delivery support.

Iluvien (fluocinolone acetonide) is used in the management of retinal vascular disease, specifically diabetic macular edema.

Diabetic macular edema (center‑involving): reduces central retinal thickness and stabilises or improves visual acuity. Diabetic macular edema (non‑center‑involving): helps maintain visual function and limits disease progression. Diabetic macular edema refractory to anti‑VEGF therapy: provides a long‑acting corticosteroid alternative for patients with inadequate response.

Common Side Effects: - Increased intraocular pressure. - Cataract formation or progression. - Ocular pain or discomfort after injection. - Vitreous floaters or visual disturbances. - Conjunctival haemorrhage. - Transient blurred vision.

Serious or Rare Side Effects: - Endophthalmitis (intraocular infection). - Retinal detachment. - Persistent elevation of intraocular pressure requiring surgical intervention. - Sterile intraocular inflammation. - Optic nerve damage. - Systemic corticosteroid effects (rare).

Prior to implantation, assess the patient’s risk for glaucoma and cataract development. - Intraocular pressure monitoring: schedule regular IOP checks after insertion. - Cataract surveillance: monitor phakic eyes for lens opacity. - Avoid use in eyes with active infection or inflammation. - Pregnancy and lactation: only use if the potential benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fluocinolone acetonide may interact with other agents that affect ocular pressure or steroid metabolism.

Major Interactions (Avoid): - Systemic corticosteroids: additive risk of elevated intraocular pressure. - Concurrent intraocular steroids: cumulative steroid load may increase IOP. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise local steroid exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants: potential for increased intraocular bleeding post‑injection. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect wound healing. - Antihypertensive agents: monitor blood pressure if systemic absorption occurs.